{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:13:03Z","timestamp":1792800783846,"version":"4.5.0"},"reference-count":77,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5F30CA275269"],"award-info":[{"award-number":["5F30CA275269"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA249175"],"award-info":[{"award-number":["5R01CA249175"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24 CA224319"],"award-info":[{"award-number":["U24 CA224319"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 DK124165"],"award-info":[{"award-number":["U01 DK124165"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA196521"],"award-info":[{"award-number":["P30 CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Merck Oncology Translational Studies Program Award"],"award-info":[{"award-number":["Merck Oncology Translational Studies Program Award"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32CA078207"],"award-info":[{"award-number":["5T32CA078207"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint blockade (ICB) has revolutionized treatment for urothelial bladder cancer, yet response rates remain limited. Inflammation promotes disease progression and treatment resistance, with macrophages shaping the tumor microenvironment (TME). Although elevated blood C-reactive protein (CRP) is associated with poor clinical outcomes in urothelial bladder cancer, its relationship to the TME remains unclear. In this study, we show that elevated plasma IL6 and CRP associate with increased tumor macrophage infiltration across multiple ICB-treated cohorts. Single-cell RNA sequencing (RNA-seq) of the largest urothelial bladder cancer atlas to date, integrated with bulk RNA-seq, identifies enrichment of immunosuppressive SPP1+ macrophages in TMEs from patients with high plasma IL6. Spatial and functional analyses demonstrate that SPP1+ macrophages suppress T-cell activity partly via IL6 signaling, whereas CXCL9+ macrophages promote T-cell activation. These findings link systemic inflammation to local immune dysfunction and define a macrophage-driven axis associated with ICB resistance and therapeutic targets to improve immunotherapy outcomes in urothelial bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Single-cell and bulk RNA-seq, spatial analyses, and functional experiments identify opposing SPP1+ and CXCL9+ macrophage programs that regulate T-cell function and ICB therapy response in bladder cancer. Elevated plasma CRP and IL6 mark SPP1+ macrophage\u2013driven immune suppression, defining a targetable IL1\u03b2\/IL6 axis that contributes to immunotherapy resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-1774","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:46:32Z","timestamp":1772142392000},"page":"1126-1151","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Tumor-Promoting Inflammatory\n                    <i>SPP1<\/i>\n                    + Macrophage\u2013IL6\u2013CRP Axis Drives Immune Dysfunction in Bladder Cancer"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-0872","authenticated-orcid":false,"given":"Michelle A.","family":"Tran","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7709","authenticated-orcid":false,"given":"Byuri Angela","family":"Cho","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 3 Department of Oncological Sciences, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8948-5689","authenticated-orcid":false,"given":"Sudeh","family":"Izadmehr","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-7050","authenticated-orcid":false,"given":"Seong-Keun","family":"Yoo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 3 Department of Oncological Sciences, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2535-7886","authenticated-orcid":false,"given":"Dina","family":"Youssef","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-0346","authenticated-orcid":false,"given":"Jonathan F.","family":"Anker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-9473","authenticated-orcid":false,"given":"Adam M.","family":"Farkas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5461-804X","authenticated-orcid":false,"given":"Igor","family":"Figueiredo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2272-5338","authenticated-orcid":false,"given":"Karen","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-9952","authenticated-orcid":false,"given":"Aparna","family":"Ananthanarayanan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2092-5145","authenticated-orcid":false,"given":"Sreekumar","family":"Balan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-290X","authenticated-orcid":false,"given":"Sayali","family":"Onkar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-6445","authenticated-orcid":false,"given":"Romain","family":"Banchereau","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gndp242","id-type":"ROR","asserted-by":"publisher"}],"name":"Genentech 4 , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7813-6627","authenticated-orcid":false,"given":"Saurabh","family":"Gupta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"publisher"}],"name":"Bristol Myers Squibb 5 , Princeton, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0675-9096","authenticated-orcid":false,"given":"Aparna","family":"Chhibber","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"publisher"}],"name":"Bristol Myers Squibb 5 , Princeton, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-4218","authenticated-orcid":false,"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-9977","authenticated-orcid":false,"given":"Kristin G.","family":"Beaumont","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 6 Department of Genomics, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-8478","authenticated-orcid":false,"given":"Ziao","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-4008","authenticated-orcid":false,"given":"Monica","family":"Garcia-Barros","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 7 Department of Pathology, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-9801","authenticated-orcid":false,"given":"Mesude","family":"Bicak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-5624","authenticated-orcid":false,"given":"Carlos","family":"Cordon-Cardo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 7 Department of Pathology, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-517X","authenticated-orcid":false,"given":"Rachel","family":"Brody","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 7 Department of Pathology, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-4400","authenticated-orcid":false,"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2375-0343","authenticated-orcid":false,"given":"Kobe","family":"Yuen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gndp242","id-type":"ROR","asserted-by":"publisher"}],"name":"Genentech 4 , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-773X","authenticated-orcid":false,"given":"Sanjeev","family":"Mariathasan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gndp242","id-type":"ROR","asserted-by":"publisher"}],"name":"Genentech 4 , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-9017","authenticated-orcid":false,"given":"Saad O.","family":"Atiq","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-0731","authenticated-orcid":false,"given":"Tolulope T.","family":"Adeyelu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wh5hg83","id-type":"ROR","asserted-by":"publisher"}],"name":"Caris Life Sciences 8 , Irving, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wh5hg83","id-type":"ROR","asserted-by":"publisher"}],"name":"Caris Life Sciences 8 , Irving, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kb97560","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Seidman Cancer Center 9 , Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"10Moores Cancer Center, University of California San Diego, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-9520","authenticated-orcid":false,"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-0626","authenticated-orcid":false,"given":"Edgar","family":"Gonzalez-Kozlova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8648-0410","authenticated-orcid":false,"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 11 Department of Urology, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3100-2810","authenticated-orcid":false,"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 3 Department of Oncological Sciences, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-0266","authenticated-orcid":false,"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 11 Department of Urology, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-5545","authenticated-orcid":false,"given":"Diego","family":"Chowell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 3 Department of Oncological Sciences, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-4187","authenticated-orcid":false,"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Immunology and Immunotherapy, The Marc and Jennifer Lipschultz Precision Immunology Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04wh5hg83","id-type":"ROR","asserted-by":"publisher"}],"name":"Caris Life Sciences 8 , Irving, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026060103142323400_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"2026060103142323400_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"2026060103142323400_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026060103142323400_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2026060103142323400_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12032-017-1029-8","article-title":"Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer","volume":"34","author":"Katz","year":"2017","journal-title":"Med Oncol"},{"key":"2026060103142323400_bib6","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026060103142323400_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026060103142323400_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026060103142323400_bib9","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"2026060103142323400_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41585-024-00858-y","article-title":"Pembrolizumab plus enfortumab vedotin in urothelial cancer","volume":"21","author":"Santoni","year":"2024","journal-title":"Nat Rev Urol"},{"key":"2026060103142323400_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2026060103142323400_bib12","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1158\/1078-0432.CCR-20-4574","article-title":"Myeloid cell\u2013associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026060103142323400_bib13","doi-asserted-by":"crossref","first-page":"16502","DOI":"10.1200\/JCO.2023.41.16_suppl.e16502","article-title":"C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: a meta-analysis","volume":"41","author":"Fujiwara","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026060103142323400_bib14","doi-asserted-by":"crossref","first-page":"e0143080","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"key":"2026060103142323400_bib15","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","article-title":"Natural killer cell accumulation in tumors is dependent on IFN-\u03b3 and CXCR3 ligands","volume":"68","author":"Wendel","year":"2008","journal-title":"Cancer Res"},{"key":"2026060103142323400_bib16","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"2026060103142323400_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"2026060103142323400_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1200\/JCO.2025.43.5_suppl.739","article-title":"Real-world analysis of 2IR immune response score in urothelial carcinoma (UC)","volume":"43","author":"Brown","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060103142323400_bib19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2026060103142323400_bib20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"2026060103142323400_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"2026060103142323400_bib22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"JCO"},{"key":"2026060103142323400_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"2026060103142323400_bib24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI117474","article-title":"The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo","volume":"94","author":"Hutchinson","year":"1994","journal-title":"J Clin Invest"},{"key":"2026060103142323400_bib25","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1172\/JCI116336","article-title":"Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease","volume":"91","author":"Vigushin","year":"1993","journal-title":"J Clin Invest"},{"key":"2026060103142323400_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"},{"key":"2026060103142323400_bib27","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"2026060103142323400_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.1840120517","article-title":"Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6","volume":"12","author":"Castell","year":"1990","journal-title":"Hepatology"},{"key":"2026060103142323400_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0006-291X(88)80043-3","article-title":"Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines","volume":"157","author":"Ganapathi","year":"1988","journal-title":"Biochem Biophysical Res Commun"},{"key":"2026060103142323400_bib30","doi-asserted-by":"crossref","first-page":"101509","DOI":"10.1016\/j.smim.2021.101509","article-title":"Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair","volume":"54","author":"Sehgal","year":"2021","journal-title":"Semin Immunol"},{"key":"2026060103142323400_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"2026060103142323400_bib32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"2026060103142323400_bib33","doi-asserted-by":"crossref","first-page":"100878","DOI":"10.1016\/j.xcrm.2022.100878","article-title":"CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026060103142323400_bib34","doi-asserted-by":"crossref","first-page":"e20240045","DOI":"10.1084\/jem.20240045","article-title":"Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment","volume":"221","author":"Tran","year":"2024","journal-title":"J Exp Med"},{"key":"2026060103142323400_bib35","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/1535-7163.MCT-22-0130","article-title":"Tumor-infiltrating myeloid cells confer de novo resistance to PD-L1 blockade through EMT\u2013stromal and Tgf\u03b2-dependent mechanisms","volume":"21","author":"Yu","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026060103142323400_bib36","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","article-title":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer","volume":"40","author":"Salom\u00e9","year":"2022","journal-title":"Cancer Cell"},{"key":"2026060103142323400_bib37","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"2026060103142323400_bib38","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"2026060103142323400_bib39","doi-asserted-by":"crossref","first-page":"109928","DOI":"10.1016\/j.isci.2024.109928","article-title":"Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"key":"2026060103142323400_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"2026060103142323400_bib41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"2026060103142323400_bib42","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"2026060103142323400_bib43","doi-asserted-by":"crossref","first-page":"e20240957","DOI":"10.1084\/jem.20240957","article-title":"Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis","volume":"222","author":"Ray","year":"2025","journal-title":"J Exp Med"},{"key":"2026060103142323400_bib44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2026060103142323400_bib45","doi-asserted-by":"crossref","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","article-title":"The gene ontology knowledgebase in 2023","volume":"224","author":"The Gene Ontology Consortium","year":"2023","journal-title":"Genetics"},{"key":"2026060103142323400_bib46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41419-018-0391-6","article-title":"The role of osteopontin in the progression of solid organ tumour","volume":"9","author":"Zhao","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026060103142323400_bib47","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1073\/pnas.96.17.9792","article-title":"Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells","volume":"96","author":"Bakker","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026060103142323400_bib48","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.4049\/jimmunol.164.10.4991","article-title":"Cutting edge: inflammatory responses can Be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes","volume":"164","author":"Bouchon","year":"2000","journal-title":"J Immunol"},{"key":"2026060103142323400_bib49","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0161-5890(02)00004-4","article-title":"TREM-1 , MDL-1 , and DAP12 expression is associated with a mature stage of myeloid development","volume":"38","author":"Gingras","year":"2002","journal-title":"Mol Immunol"},{"key":"2026060103142323400_bib50","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026060103142323400_bib51","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"2026060103142323400_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","article-title":"IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy","volume":"19","author":"Du","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"2026060103142323400_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/343341a0","article-title":"Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist","volume":"343","author":"Eisenberg","year":"1990","journal-title":"Nature"},{"key":"2026060103142323400_bib54","doi-asserted-by":"crossref","first-page":"26748","DOI":"10.1074\/jbc.M400785200","article-title":"IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness","volume":"279","author":"Qin","year":"2004","journal-title":"J Biol Chem"},{"key":"2026060103142323400_bib55","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","article-title":"Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies","volume":"11","author":"Gummadi","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"2026060103142323400_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2326-6066.CIR-22-0462","article-title":"High-resolution analysis of mononuclear phagocytes reveals GPNMB as a prognostic marker in human colorectal liver metastasis","volume":"11","author":"Cortese","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026060103142323400_bib57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41551-025-01475-9","article-title":"Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline","volume":"10","author":"Buckup","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"2026060103142323400_bib58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ni931","article-title":"SOCS3 negatively regulates IL-6 signaling in vivo","volume":"4","author":"Croker","year":"2003","journal-title":"Nat Immunol"},{"key":"2026060103142323400_bib59","doi-asserted-by":"crossref","first-page":"111384","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2021","journal-title":"Cell Rep"},{"key":"2026060103142323400_bib60","doi-asserted-by":"crossref","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026060103142323400_bib61","doi-asserted-by":"crossref","first-page":"112940","DOI":"10.1016\/j.celrep.2023.112940","article-title":"SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine","volume":"42","author":"Mise-Omata","year":"2023","journal-title":"Cell Rep"},{"key":"2026060103142323400_bib62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non\u2013small-cell lung cancer: results from the CANOPY-1 trial","volume":"42","author":"Tan","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026060103142323400_bib63","doi-asserted-by":"crossref","first-page":"S953","DOI":"10.1016\/j.annonc.2021.08.1799","article-title":"1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2\/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results","volume":"32","author":"Paz-Ares","year":"2021","journal-title":"Ann Oncol"},{"key":"2026060103142323400_bib64","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/1078-0432.CCR-23-0798","article-title":"Atezolizumab plus magrolimab, niraparib, or tocilizumab versus atezolizumab monotherapy in platinum-refractory metastatic urothelial carcinoma: a phase Ib\/II open-label, multicenter, randomized umbrella study (MORPHEUS urothelial carcinoma)","volume":"29","author":"Drakaki","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026060103142323400_bib65","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2026060103142323400_bib66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026060103142323400_bib67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2026060103142323400_bib68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","article-title":"DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors","volume":"8","author":"McGinnis","year":"2019","journal-title":"Cell Syst"},{"key":"2026060103142323400_bib69","doi-asserted-by":"crossref","first-page":"eadi3808","DOI":"10.1126\/science.adi3808","article-title":"An immunogenetic basis for lung cancer risk","volume":"383","author":"Krishna","year":"2024","journal-title":"Science"},{"key":"2026060103142323400_bib70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41587-021-00830-w","article-title":"Robust decomposition of cell type mixtures in spatial transcriptomics","volume":"40","author":"Cable","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026060103142323400_bib71","doi-asserted-by":"crossref","first-page":"100764","DOI":"10.1016\/j.xgen.2025.100764","article-title":"Defining hypoxia in cancer: a landmark evaluation of hypoxia gene expression signatures","volume":"5","author":"Di Giovannantonio","year":"2025","journal-title":"Cell Genomics"},{"key":"2026060103142323400_bib72","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nmeth.4463","article-title":"SCENIC: single-cell regulatory network inference and clustering","volume":"14","author":"Aibar","year":"2017","journal-title":"Nat Methods"},{"key":"2026060103142323400_bib73","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026060103142323400_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2026060103142323400_bib75","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"2026060103142323400_bib76","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.18632\/oncotarget.24807","article-title":"A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies","volume":"9","author":"Rosskopf","year":"2018","journal-title":"Oncotarget"},{"key":"2026060103142323400_bib77","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1158\/0008-5472.CAN-14-0376","article-title":"HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice","volume":"74","author":"Gschweng","year":"2014","journal-title":"Cancer Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1774\/3743618\/cd-25-1774.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1774\/3781705\/cd-25-1774.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/6\/1126\/3799055\/cd-25-1774.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/6\/1126\/3799055\/cd-25-1774.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:14:46Z","timestamp":1780298086000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/6\/1126\/785547\/A-Tumor-Promoting-Inflammatory-SPP1-Macrophage-IL6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-1774","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.32530305","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530326","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530338","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530317","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530329","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530308","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530287","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530344","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530296","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530335","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530314","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530341","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530302","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530320","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530278","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530332","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530290","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530284","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32530281","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8509389","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}